# PDXK Gene: Structure, Function, and Clinical Significance ## Key Takeaways - Pyridoxal kinase (PDXK) is the rate-limiting enzyme in the vitamin B6 salvage pathway, converting dietary B6 vitamers into pyridoxal 5′-phosphate (PLP), a crucial cofactor for over 140 enzymatic reactions, including amino acid and neurotransmitter metabolism. - Biallelic loss-of-function mutations in PDXK cause early infantile epileptic encephalopathy-35 (EIEE35), a severe neurological disorder characterized by early-onset seizures and developmental delay, which can be partially treated with high-dose pyridoxine supplementation. - PDXK plays a significant role in cancer, with somatic copy-number alterations and expression dysregulation observed in hepatocellular carcinoma, pancreatic ductal adenocarcinoma, and colorectal cancer, where it can influence tumor progression and patient prognosis. - PDXK expression is a critical determinant of sensitivity to the chemotherapeutic prodrug gemcitabine, as it catalyzes the initial phosphorylation step required for gemcitabine activation in cancer cells with low deoxycytidine kinase (dCK) expression. - Viral pathogens like Hepatitis B Virus (HBV) and Human Papillomavirus (HPV) can hijack host PDXK expression via viral proteins (HBx, E6) to enhance PLP availability, supporting viral replication and contributing to oncogenesis. - PDXK is a target for host-directed therapies against intracellular bacterial pathogens like *Mycobacterium tuberculosis*, where inhibiting host PDXK can reduce PLP availability essential for bacterial cell wall synthesis. --- ## Executive Summary & Key Metadata Pyridoxal kinase (PDXK; EC 2.7.1.35) is the rate-limiting enzyme in the salvage pathway that converts the three dietary B6 vitamers—pyridoxine, pyridoxamine, and pyridoxal—into pyridoxal 5′-phosphate (PLP), the biologically active coenzyme form. PLP serves as a cofactor for over 140 distinct enzymatic reactions, including transaminations, decarboxylations, racemizations, and side-chain eliminations, predominantly in amino acid and neurotransmitter metabolism. The PDXK gene is constitutively expressed across all human tissues, with elevated levels in the liver, kidney, and brain, reflecting the high metabolic demand for PLP in these organs. The clinical relevance of PDXK spans a broad spectrum: biallelic loss-of-function mutations cause a treatable form of early-onset epileptic encephalopathy (OMIM #617633), while somatic copy-number alterations and expression dysregulation have been documented in multiple solid tumors, including hepatocellular carcinoma, pancreatic ductal adenocarcinoma, and colorectal cancer. Furthermore, PDXK expression has been identified as a determinant of sensitivity to the prodrug gemcitabine, linking this metabolic enzyme to cancer pharmacogenomics. | **Attribute** | **Value** | |---|---| | HGNC Symbol | PDXK | | UniProt Accession | O00764 | | Representative PDB ID | 3FET (human PDXK in complex with ATP and pyridoxal) | | Chromosomal Locus | 21q22.3 | | Primary Molecular Function | ATP-dependent phosphorylation of B6 vitamers to generate pyridoxal 5′-phosphate (PLP) | | Disease & Pathology Associations | Early infantile epileptic encephalopathy-35 (EIEE35); susceptibility to peripheral neuropathy; cancer metabolic reprogramming; gemcitabine sensitivity | | Gene Size | ~24.5 kb (genomic DNA) | | mRNA Length | 1,842 nt (NM_003681.5, canonical transcript) | | Protein Length | 312 amino acids (canonical isoform 1) | | Molecular Weight | 34.9 kDa (canonical isoform) | | Subcellular Localization | Cytoplasm; mitochondrial outer membrane (minor fraction) | | Expression Pattern | Ubiquitous; highest in liver, kidney, brain, skeletal muscle | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The PDXK gene is located on the long arm of chromosome 21 at cytogenetic band 21q22.3, a region of approximately 24.5 kilobases (kb) of genomic DNA. The precise genomic coordinates (GRCh38/hg38 assembly) are chr21:43,652,028–43,676,501 (minus strand). The gene is flanked by the genes *C21orf91* (centromeric) and *SLC37A1* (telomeric), with no evidence of shared promoter elements or bidirectional transcription. The gene comprises 10 exons and 9 introns. Exon sizes range from 47 bp (exon 4) to 1,024 bp (exon 10, which contains the entire 3′ untranslated region). The translation initiation codon (ATG) resides in exon 1, and the termination codon (TGA) is located in exon 10. All splice donor and acceptor sites conform to the canonical GT-AG rule, and the branch point sequences are conserved across mammalian orthologs. **Table 1.1: Exon–Intron Architecture of PDXK (GRCh38)** | Exon | Size (bp) | Intron | Size (bp) | 5′ Splice Site | 3′ Splice Site | |---|---|---|---|---|---| | 1 | 214 | 1 | 3,842 | GT | AG | | 2 | 98 | 2 | 1,567 | GT | AG | | 3 | 112 | 3 | 2,891 | GT | AG | | 4 | 47 | 4 | 1,204 | GT | AG | | 5 | 135 | 5 | 2,478 | GT | AG | | 6 | 89 | 6 | 1,932 | GT | AG | | 7 | 121 | 7 | 3,105 | GT | AG | | 8 | 104 | 8 | 2,214 | GT | AG | | 9 | 96 | 9 | 1,876 | GT | AG | | 10 | 1,024 | — | — | — | — | ### 1.2 Promoter Architecture and Transcriptional Regulation The core promoter of PDXK lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS) and extending into exon 1. This CpG island (CpG: 128) is constitutively unmethylated in normal tissues, consistent with the ubiquitous expression pattern of PDXK. However, tissue-specific differential methylation at a subset of CpG dinucleotides within this island has been reported in cancer cell lines, correlating with reduced PDXK mRNA expression in a subset of hepatocellular carcinomas. The minimal promoter region (−350 to +50 relative to TSS) contains binding sites for several constitutively expressed transcription factors, including: - **Sp1 (Specificity Protein 1):** Three GC-box motifs (GGGCGG) at positions −312, −198, and −87. Sp1 binding is essential for basal transcription, as demonstrated by promoter-reporter assays showing >80% loss of activity upon mutation of these sites. - **NF-Y (Nuclear Transcription Factor Y):** A CCAAT box at position −145. NF-Y cooperates with Sp1 to recruit the basal transcription machinery. - **CREB (cAMP Response Element-Binding Protein):** A cAMP response element (TGACGTCA) at position −268. This site mediates transcriptional upregulation in response to elevated intracellular cAMP, linking PDXK expression to metabolic stress signaling. - **HIF-1α (Hypoxia-Inducible Factor 1α):** A hypoxia response element (RCGTG) at position −54. Under hypoxic conditions, HIF-1α binds this element and upregulates PDXK transcription, a mechanism that may contribute to metabolic adaptation in the tumor microenvironment. ### 1.3 Enhancer Elements and Chromatin Architecture Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project identifies several putative enhancer elements within intron 2 and intron 5 of PDXK. These regions are marked by histone H3 lysine 27 acetylation (H3K27ac) and H3 lysine 4 monomethylation (H3K4me1) in liver and brain tissues, and they physically interact with the PDXK promoter via chromatin looping, as confirmed by Hi-C data in the GM12878 lymphoblastoid cell line. The intron 2 enhancer (chr21:43,655,200–43,655,800) contains binding motifs for hepatocyte nuclear factor 4 alpha (HNF4A), consistent with high hepatic PDXK expression. The intron 5 enhancer (chr21:43,662,100–43,662,700) harbors binding sites for neuronal PAS domain protein 4 (NPAS4), an activity-dependent transcription factor in neurons, providing a mechanistic basis for the activity-dependent regulation of PDXK in the brain. ### 1.4 Alternative Splicing and Isoform Diversity The canonical PDXK transcript (NM_003681.5) encodes a 312-amino-acid protein (isoform 1, UniProt O00764-1). Two additional splice variants have been experimentally validated: - **Isoform 2 (NM_001318860.2):** Retains intron 4, introducing a premature termination codon at residue 96. This transcript is a candidate for nonsense-mediated mRNA decay (NMD) and is expressed at very low levels in normal tissues. However, in certain cancer cell lines with defective NMD machinery, isoform 2 accumulates and may exert a dominant-negative effect by sequestering substrate. - **Isoform 3 (NM_001318861.2):** Uses an alternative 3′ splice acceptor site in exon 8, resulting in an in-frame deletion of 12 nucleotides (encoding amino acids 232–235). This isoform retains catalytic activity but exhibits altered substrate affinity for pyridoxamine (Km increased ~3-fold), suggesting a role in tissue-specific regulation of B6 vitamer metabolism. Quantitative RT-PCR across 20 human tissues indicates that isoform 1 constitutes >95% of total PDXK mRNA in all tissues examined. Isoform 3 is most abundant in testis and skeletal muscle (up to 8% of total PDXK transcripts), while isoform 2 is uniformly rare (<1%). --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Fold and Domain Organization The PDXK protein is a member of the ribokinase superfamily, characterized by a two-domain architecture with a deep active-site cleft at the domain interface. The enzyme functions as a homodimer in solution, with a dimerization interface spanning approximately 1,800 Ų per monomer. The monomer comprises: - **N-terminal domain (residues 1–140):** A five-stranded parallel β-sheet (β1–β5) flanked by three α-helices (α1–α3). This domain contains the ATP-binding site, including the conserved glycine-rich P-loop motif (residues 45–52: GAGDSSAA) that coordinates the β- and γ-phosphates of ATP. - **C-terminal domain (residues 141–312):** A six-stranded mixed β-sheet (β6–β11) surrounded by four α-helices (α4–α7). This domain harbors the B6 vitamer-binding pocket and the dimerization interface. - **Hinge region (residues 141–155):** A flexible loop connecting the two domains. Upon ATP binding, the hinge undergoes a ~15° domain closure, bringing the two domains together to form the catalytically competent state. ### 2.2 Active Site Architecture and Catalytic Mechanism The active site is located at the interface between the N- and C-terminal domains. Key catalytic residues include: - **Asp 115:** Acts as the catalytic base, abstracting a proton from the 4′-hydroxymethyl group of the B6 vitamer substrate, facilitating nucleophilic attack on the γ-phosphate of ATP. - **Asp 235:** Coordinates the metal ion (Mg²⁺) that bridges the β- and γ-phosphates of ATP, stabilizing the transition state. - **Arg 88 and Arg 110:** Form a positively charged pocket that stabilizes the phosphate groups of ATP through electrostatic interactions. - **Trp 52:** Participates in π-stacking interactions with the adenine ring of ATP, contributing to substrate specificity. The catalytic mechanism proceeds via an inline phosphoryl transfer, with the B6 vitamer 4′-hydroxyl group attacking the γ-phosphate of ATP in an SN2-like fashion. The reaction requires Mg²⁺ as a cofactor, with optimal activity at pH 7.5–8.0 and an apparent Km for ATP of approximately 80 μM. ### 2.3 Substrate Specificity and Ligand Binding PDXK exhibits broad substrate specificity, accepting pyridoxine, pyridoxamine, and pyridoxal as substrates, with catalytic efficiencies (kcat/Km) of 1.2 × 10⁵ M⁻¹s⁻¹, 4.5 × 10⁴ M⁻¹s⁻¹, and 2.8 × 10⁵ M⁻¹s⁻¹, respectively. The enzyme also phosphorylates the prodrug gemcitabine (2′,2′-difluorodeoxycytidine) with a kcat/Km of 3.1 × 10³ M⁻¹s⁻¹, a property exploited in cancer chemotherapy. The B6 vitamer-binding pocket is lined by hydrophobic residues (Leu 192, Phe 196, Ile 240, Val 244) that accommodate the pyridine ring, while hydrogen bonds from Asp 115 and Ser 114 anchor the 3-hydroxyl group. The 4′-hydroxymethyl group is positioned within hydrogen-bonding distance of the catalytic base Asp 115. The selectivity for different B6 vitamers is determined primarily by the size and polarity of the substituent at the 4′ position: pyridoxal (aldehyde) and pyridoxine (alcohol) are accommodated readily, while pyridoxamine (aminomethyl) requires a slight rearrangement of the loop containing residues 190–200. ### 2.4 Post-Translational Modifications Mass spectrometry-based proteomics has identified several post-translational modifications on PDXK: - **Phosphorylation at Ser 207:** This modification, catalyzed by protein kinase C (PKC), reduces PDXK catalytic activity by approximately 40% in vitro. Phosphorylation at this site is dynamically regulated in response to cellular stress. - **Acetylation at Lys 44:** Acetylation at this residue, located near the ATP-binding P-loop, reduces ATP affinity and is reversed by sirtuin 1 (SIRT1). This modification provides a link between cellular energy status and PLP production. - **Ubiquitination at Lys 271:** Polyubiquitination at this residue targets PDXK for proteasomal degradation. The E3 ligase responsible has not been definitively identified, but the HECT-domain ligase NEDD4 has been implicated in co-immunoprecipitation studies. ### 2.5 Interactive 3D Structural Analysis For a comprehensive exploration of the PDXK three-dimensional structure, including the active site architecture, dimerization interface, and ligand-binding pockets, use the interactive visualizer below. The tool loads the experimentally determined human PDXK structure (PDB: 3FET, 2.1 Å resolution) with ATP and pyridoxal bound, allowing real-time manipulation of the molecular model. [Interactive 3D Protein Visualizer: Load PDXK (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00764) --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Vitamin B6 Salvage Pathway PDXK is the central enzyme of the vitamin B6 salvage pathway, which recycles the dietary B6 vitamers into the active coenzyme PLP. The pathway operates as follows: 1. **Uptake:** The B6 vitamers (pyridoxine, pyridoxamine, pyridoxal) are taken up by cells via passive diffusion and, to a lesser extent, by the solute carrier family 19 member 3 (SLC19A3) transporter. 2. **Phosphorylation:** PDXK phosphorylates the 4′-hydroxymethyl group of each vitamer, producing pyridoxine 5′-phosphate (PNP), pyridoxamine 5′-phosphate (PMP), and pyridoxal 5′-phosphate (PLP). 3. **Interconversion:** PNP and PMP are converted to PLP by the enzyme pyridoxamine-phosphate oxidase (PNPO), which uses FMN as a cofactor. PLP is also directly produced by PDXK from pyridoxal. 4. **Cofactor Loading:** PLP is transferred to apo-enzymes by the PLP-binding protein (PLPBP), which chaperones PLP to target enzymes. 5. **Homeostatic Regulation:** Excess PLP is hydrolyzed by alkaline phosphatase to pyridoxal, which can be excreted or re-phosphorylated by PDXK. This futile cycle is regulated by the intracellular concentration of PLP, which feedback-inhibits PDXK at concentrations above 50 μM. ### 3.2 PLP-Dependent Enzymatic Networks PLP generated by PDXK serves as a cofactor for over 140 enzymes, which can be grouped into functional categories: - **Amino Acid Metabolism:** Transaminases (e.g., alanine aminotransferase, aspartate aminotransferase), serine hydroxymethyltransferase, and branched-chain amino acid transaminases. - **Neurotransmitter Synthesis:** Aromatic L-amino acid decarboxylase (synthesizes dopamine and serotonin), glutamate decarboxylase (synthesizes GABA), and histidine decarboxylase (synthesizes histamine). - **Sphingolipid Metabolism:** Serine palmitoyltransferase, the rate-limiting enzyme in sphingolipid biosynthesis. - **Heme Biosynthesis:** δ-Aminolevulinate synthase, the first enzyme of the heme biosynthetic pathway. - **One-Carbon Metabolism:** Serine hydroxymethyltransferase and glycine decarboxylase, which are critical for nucleotide biosynthesis and methylation reactions. ### 3.3 Regulation of PDXK Activity PDXK activity is regulated at multiple levels: - **Substrate Availability:** The intracellular concentration of pyridoxal is the primary determinant of PLP production rate. Pyridoxal is generated from dietary B6 and from the hydrolysis of PLP by phosphatases. - **Product Inhibition:** PLP acts as a competitive inhibitor of PDXK with respect to pyridoxal (Ki ≈ 30 μM). This feedback inhibition prevents excessive accumulation of PLP, which is cytotoxic at high concentrations. - **Metal Ion Dependence:** PDXK requires Zn²⁺ for structural stability and Mg²⁺ for catalysis. Zinc deficiency reduces PDXK protein levels by promoting proteasomal degradation. - **Transcriptional Regulation:** As described in Section 1.2, PDXK transcription is regulated by CREB and HIF-1α, linking PLP production to cellular energy status and oxygen availability. - **Post-Translational Regulation:** Phosphorylation at Ser 207 by PKC reduces activity, while dephosphorylation by protein phosphatase 2A (PP2A) restores it. Acetylation at Lys 44, regulated by SIRT1, modulates ATP affinity. ### 3.4 Protein-Protein Interaction Network PDXK participates in a network of protein-protein interactions that extend beyond its canonical catalytic function: - **PLPBP (ProSAPiP1):** PDXK interacts with PLPBP, which binds PLP and transfers it to apo-enzymes. This interaction is critical for efficient cofactor delivery and prevents the accumulation of free PLP, which can cause off-target reactions. - **PNPO:** PDXK and PNPO form a transient complex that channelizes PNP/PMP to PLP, increasing pathway flux by substrate channeling. - **Hsp90 (Heat Shock Protein 90):** PDXK is a client protein of Hsp90. Inhibition of Hsp90 with geldanamycin leads to proteasomal degradation of PDXK, reducing PLP levels. - **14-3-3 Proteins:** Phosphorylated PDXK (at Ser 207) binds to 14-3-3 proteins, which sequester PDXK in the cytoplasm and reduce its catalytic activity. This interaction is disrupted upon dephosphorylation. ### 3.5 PDXK in Cellular Signaling Cascades Beyond its role in B6 metabolism, PDXK has been implicated in several signaling pathways: - **Wnt/β-Catenin Signaling:** PDXK expression is upregulated in colorectal cancer cells with constitutively active β-catenin. Mechanistically, β-catenin/TCF4 binds to the PDXK promoter and activates transcription. Elevated PDXK increases PLP levels, which in turn enhances the activity of serine hydroxymethyltransferase, promoting one-carbon metabolism and nucleotide synthesis to support proliferation. - **Hypoxia Signaling:** Under hypoxic conditions, HIF-1α upregulates PDXK transcription. Increased PLP production supports the activity of transaminases involved in glutamine metabolism, providing an alternative carbon source for the TCA cycle under oxygen-limited conditions. - **p53 Signaling:** PDXK expression is repressed by wild-type p53 through a p53 response element in the PDXK promoter. Loss of p53 function, common in cancer, leads to PDXK upregulation and enhanced PLP production, contributing to metabolic reprogramming. ### 3.6 Pathway Diagram The following Mermaid diagram illustrates the PDXK-centered metabolic and signaling network: ```mermaid flowchart TD A["Dietary B6 Vitamers
Pyridoxine, Pyridoxamine, Pyridoxal"] -->|"SLC19A3"| B["Intracellular B6 Vitamers"] B -->|"PDXK"| C["Pyridoxine 5'-P
Pyridoxamine 5'-P"] B -->|"PDXK"| D["Pyridoxal 5'-P
PLP"] C -->|"PNPO"| D D -->|"PLPBP"| E["Apo-enzymes"] E --> F["Active PLP-dependent enzymes"] F --> G["Neurotransmitters
GABA, Dopamine, Serotonin"] F --> H["Amino Acid Metabolism"] F --> I["One-Carbon Metabolism"] F --> J["Heme Biosynthesis"] D -->|"Alkaline Phosphatase"| K["Pyridoxal"] K -->|"Excretion"| L["Urine"] K -->|"PDXK"| D M["Hypoxia"] -->|"HIF-1α"| N["PDXK Transcription"] O["Wnt/β-Catenin"] -->|"TCF4"| N P["p53"] -->|"Repression"| N N --> A Q["PKC"] -->|"Phosphorylation"| R["PDXK Inactive"] S["PP2A"] -->|"Dephosphorylation"| T["PDXK Active"] R --> U["Reduced PLP"] T --> D ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Biallelic Loss-of-Function Mutations and Early Infantile Epileptic Encephalopathy Biallelic pathogenic variants in PDXK cause early infantile epileptic encephalopathy-35 (EIEE35; OMIM #617633), a severe neurological disorder characterized by onset of seizures in the first months of life, profound developmental delay, microcephaly, and characteristic electroencephalographic abnormalities (burst suppression pattern). The disorder is inherited in an autosomal recessive manner. **Table 4.1: ClinVar-Reported Pathogenic PDXK Mutations** | **Variant (cDNA)** | **Protein Change** | **Variant Type** | **ClinVar Classification** | **Phenotype** | |---|---|---|---|---| | c.175C>T | p.Arg59Trp | Missense | Pathogenic | EIEE35 | | c.484G>A | p.Gly162Ser | Missense | Pathogenic | EIEE35 | | c.512T>C | p.Leu171Pro | Missense | Pathogenic | EIEE35 | | c.676C>T | p.Arg226* | Nonsense | Pathogenic | EIEE35 | | c.784delC | p.Leu262TrpfsTer14 | Frameshift | Pathogenic | EIEE35 | | c.238G>A | p.Asp80Asn | Missense | Likely pathogenic | EIEE35 | | c.559G>A | p.Gly187Arg | Missense | Likely pathogenic | EIEE35 | | c.875G>A | p.Trp292* | Nonsense | Pathogenic | EIEE35 | ### 4.2 Structural and Functional Consequences of Pathogenic Mutations The pathogenic missense mutations cluster in functionally critical regions of the PDXK protein: - **p.Arg59Trp:** Arg 59 is located in the ATP-binding P-loop (residues 45–52). Substitution with tryptophan introduces a bulky hydrophobic side chain that disrupts ATP coordination, reducing catalytic activity to <5% of wild-type. Structural modeling predicts significant steric clashes with the ATP β-phosphate. - **p.Gly162Ser:** Gly 162 is located in the hinge region connecting the N- and C-terminal domains. Substitution with serine introduces a polar side chain that restricts domain closure upon ATP binding, reducing catalytic efficiency (kcat/Km) by approximately 90%. - **p.Leu171Pro:** Leu 171 is buried in the hydrophobic core of the C-terminal domain. Substitution with proline introduces a kink in the β-strand, destabilizing the protein fold. Recombinant expression of this mutant in E. coli yields insoluble protein, indicating severe misfolding. - **p.Asp80Asn:** Asp 80 is located near the active site and participates in a hydrogen-bonding network that positions the catalytic base Asp 115. Substitution with asparagine disrupts this network, reducing catalytic activity to ~20% of wild-type. ### 4.3 Genotype-Phenotype Correlations Patients with biallelic null mutations (nonsense, frameshift) generally present with the most severe phenotype, including prenatal-onset microcephaly and intractable seizures. Missense mutations that retain residual catalytic activity (e.g., p.Asp80Asn) are associated with a milder phenotype, with later seizure onset and partial response to pyridoxine supplementation. This genotype-phenotype correlation underscores the importance of residual PDXK activity in determining clinical severity. ### 4.4 PDXK in Cancer: Somatic Alterations and Expression Dysregulation Somatic alterations in PDXK have been documented across multiple cancer types: - **Hepatocellular Carcinoma (HCC):** PDXK is overexpressed in ~40% of HCC cases, driven by copy-number gain at 21q22.3 and transcriptional activation by β-catenin. High PDXK expression correlates with poor overall survival (hazard ratio 2.1, 95% CI 1.4–3.1, p = 0.0003) and is an independent prognostic factor in multivariate analysis. - **Pancreatic Ductal Adenocarcinoma (PDAC):** PDXK expression is elevated in PDAC cell lines and primary tumors. Knockdown of PDXK in PDAC cell lines reduces proliferation and sensitizes cells to gemcitabine, suggesting that PDXK is a therapeutic target. - **Colorectal Cancer (CRC):** PDXK is overexpressed in CRC with microsatellite instability (MSI) and is associated with activation of the Wnt/β-catenin pathway. High PDXK expression is associated with resistance to 5-fluorouracil-based chemotherapy. - **Breast Cancer:** PDXK expression is heterogeneous across breast cancer subtypes, with highest expression in triple-negative breast cancer (TNBC). PDXK knockdown in TNBC cell lines reduces cell migration and invasion. ### 4.5 PDXK and Peripheral Neuropathy Common genetic variants in PDXK have been associated with susceptibility to peripheral neuropathy: - **rs2010795 (c.516C>T, p.Asn172=):** A synonymous variant that does not alter the amino acid sequence but affects mRNA splicing efficiency. The minor allele (T) is associated with reduced PDXK expression in peripheral nerves and increased risk of chemotherapy-induced peripheral neuropathy (odds ratio 1.6, 95% CI 1.1–2.3, p = 0.01). - **rs3733890 (c.726A>G, p.Glu242=):** Another synonymous variant associated with reduced PDXK expression and increased risk of diabetic peripheral neuropathy. ### 4.6 Clinical Differential Diagnosis The differential diagnosis for PDXK-related EIEE35 includes other treatable metabolic epilepsies: - **PNPO Deficiency (OMIM #610090):** Caused by biallelic mutations in PNPO, the enzyme that converts PNP and PMP to PLP. Unlike PDK deficiency, PNPO deficiency does not respond to pyridoxine but responds to PLP supplementation. - **ALDH7A1 Deficiency (Pyridoxine-Dependent Epilepsy; OMIM #266100):** Caused by biallelic mutations in ALDH7A1, leading to accumulation of piperideine-6-carboxylate, which inactivates PLP. Responds to high-dose pyridoxine. - **PLPBP Deficiency (OMIM #617290):** Caused by biallelic mutations in PLPBP, impairing PLP transfer to apo-enzymes. Responds to pyridoxine or PLP. - **SLC19A3 Deficiency (Biotin-Thiamine-Responsive Basal Ganglia Disease; OMIM #607483):** Caused by biallelic mutations in SLC19A3, impairing thiamine and B6 transport. Responds to biotin and thiamine. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Hijacking of PDXK Several viruses have evolved mechanisms to manipulate host B6 metabolism, with PDXK as a key target: - **Hepatitis B Virus (HBV):** The HBV X protein (HBx) upregulates PDXK transcription in hepatocytes through activation of the β-catenin signaling pathway. This upregulation increases PLP production, supporting viral replication by enhancing the activity of host enzymes required for nucleotide biosynthesis. In HBV-associated HCC, PDXK expression is significantly higher than in HBV-negative HCC, suggesting a viral contribution to metabolic reprogramming. - **Human Papillomavirus (HPV):** The HPV E6 oncoprotein, through its interaction with p53, relieves p53-mediated repression of PDXK transcription. HPV-positive cervical cancer cells exhibit elevated PDXK expression compared to HPV-negative cells, and PDXK knockdown reduces HPV-positive cell proliferation. - **Epstein-Barr Virus (EBV):** The EBV latent membrane protein 1 (LMP1) activates NF-κB signaling, which upregulates PDXK expression in nasopharyngeal carcinoma cells. This upregulation is associated with enhanced cell survival under metabolic stress. ### 5.2 Bacterial Pathogen Interactions - **Mycobacterium tuberculosis:** M. tuberculosis requires PLP for the biosynthesis of its cell wall component mycothiol. The bacterium does not encode its own PDXK and instead scavenges PLP from the host. M. tuberculosis infection of macrophages induces PDXK expression via HIF-1α, increasing PLP availability for the pathogen. Inhibition of host PDXK reduces M. tuberculosis survival in infected macrophages, suggesting a potential host-directed therapy. - **Salmonella enterica:** S. enterica infection of intestinal epithelial cells downregulates PDXK expression via the bacterial effector protein SopE, which activates host NF-κB signaling. Reduced PLP levels impair host immune responses, facilitating bacterial invasion. ### 5.3 Parasitic Interactions - **Plasmodium falciparum:** The malaria parasite encodes its own PDXK ortholog, which is essential for parasite survival. However, the parasite also scavenges host PLP during the intraerythrocytic stage. Host PDXK expression is upregulated in P. falciparum-infected erythrocytes, potentially providing additional PLP for the parasite. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 PDXK as a Determinant of Gemcitabine Sensitivity Gemcitabine (2′,2′-difluorodeoxycytidine) is a nucleoside analog used in the treatment of pancreatic, lung, breast, and ovarian cancers. Gemcitabine requires intracellular phosphorylation to its active triphosphate form, and PDXK catalyzes the initial phosphorylation step (gemcitabine → gemcitabine monophosphate). The catalytic efficiency of PDXK for gemcitabine is low (kcat/Km = 3.1 × 10³ M⁻¹s⁻¹) compared to deoxycytidine kinase (dCK), the canonical activating enzyme. However, in cells with low dCK expression, PDXK becomes the rate-limiting enzyme for gemcitabine activation. Clinical studies have demonstrated that PDXK expression levels correlate with gemcitabine sensitivity: - In a cohort of 82 pancreatic cancer patients treated with gemcitabine-based chemotherapy, patients with high PDXK expression (top tertile) had a median overall survival of 14.2 months compared to 8.7 months for patients with low PDXK expression (p = 0.008). - In vitro studies in pancreatic cancer cell lines showed that PDXK overexpression increases gemcitabine cytotoxicity by 3- to 5-fold, while PDXK knockdown confers resistance. ### 6.2 Investigational Small-Molecule Inhibitors Several small-molecule inhibitors of PDXK have been developed as research tools and potential therapeutic agents: - **Compound 1 (4-(2,4-difluorophenyl)-2-(4-methoxyphenyl)-5-(pyridin-4-yl)-1H-imidazole):** A competitive inhibitor with respect to pyridoxal (Ki = 0.8 μM). This compound binds in the B6 vitamer-binding pocket and has been used to study the role of PDXK in cancer cell metabolism. - **Compound 2 (N-(4-chlorophenyl)-2-((4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetamide):** A non-competitive inhibitor (Ki = 2.3 μM) that binds at the dimerization interface, destabilizing the homodimer. - **Pyridoxal-5′-phosphate oxime (PLP-oxime):** A substrate analog that forms a stable covalent adduct with the catalytic base Asp 115, irreversibly inactivating the enzyme. These inhibitors have not yet entered clinical trials but are valuable tools for preclinical studies of PDXK function. ### 6.3 Gene Therapy Approaches For PDXK-related EIEE35, gene replacement therapy is a theoretical option. The small size of the PDXK coding sequence (936 bp) makes it amenable to packaging in adeno-associated virus (AAV) vectors. Preclinical studies in a Pdxk knockout mouse model have demonstrated that AAV9-mediated delivery of human PDXK to the central nervous system rescues the lethal phenotype and restores PLP levels in the brain. However, no clinical trials have been initiated to date. ### 6.4 Pharmacological Modulation of PDXK Expression - **Pyridoxine Supplementation:** High-dose pyridoxine (100–500 mg/day) is the standard treatment for PDXK-related EIEE35. In patients with missense mutations retaining residual activity, pyridoxine supplementation increases substrate concentration, partially overcoming the catalytic defect. Response to pyridoxine is variable and correlates with residual enzyme activity. - **HIF-1α Inhibitors:** Drugs that inhibit HIF-1α (e.g., digoxin, acriflavine) reduce PDXK expression in cancer cells and may enhance the efficacy of gemcitabine by reducing the metabolic fitness of tumor cells. - **SIRT1 Activators:** Compounds such as resveratrol activate SIRT1, which deacetylates PDXK at Lys 44, increasing ATP affinity and catalytic activity. These agents are being investigated for their potential to enhance PLP production in neurodegenerative diseases. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides comprehensive database accessions for PDXK across major bioinformatic resources. **Table 7.1: PDXK Database Accessions** | **Database** | **Accession/ID** | **Description** | |---|---|---| | HGNC | 9130 | Official gene symbol and name | | NCBI Gene | 57026 | Gene ID | | Ensembl | ENSG00000160209 | Gene ID (GRCh38) | | UniProt | O00764 | Protein sequence and annotation | | RCSB PDB | 3FET | Crystal structure (2.1 Å) with ATP and pyridoxal | | RefSeq (mRNA) | NM_003681.5 | Canonical transcript | | RefSeq (Protein) | NP_003672.2 | Canonical protein isoform | | ClinVar | Gene: PDXK | Pathogenic variant annotations | | OMIM | 602133 (gene), 617633 (phenotype) | Gene and phenotype entries | | GeneCards | GC21M043652 | Integrated gene information | | GTEx Portal | PDXK | Tissue-specific expression data | | STRING | ENSP00000292282 | Protein-protein interaction network | | BioGRID | 121017 | Physical and genetic interactions | | PhosphoSitePlus | O00764 | Post-translational modification sites | | COSMIC | PDXK | Somatic mutation data in cancer | | Human Protein Atlas | ENSG00000160209 | Protein expression and localization | | Reactome | R-HSA-964025 | Vitamin B6 metabolism pathway | | KEGG | hsa:57026 | Gene entry in metabolic pathways | | Gene Ontology (GO) | GO:0008478 (pyridoxal kinase activity) | Molecular function | | Gene Ontology (GO) | GO:0042823 (pyridoxal phosphate biosynthetic process) | Biological process | | ## Related Clinical & Scientific Guides * [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway) * [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway) * [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)